VCT 220
Alternative Names: CX-11; VCT-220Latest Information Update: 29 Jun 2026
At a glance
- Originator Vincentage Pharma
- Developer Corxel Pharmaceuticals; Vincentage Pharma
- Class Antihyperglycaemics; Antihypertensives; Obesity therapies; Small molecules
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Obesity
- Phase II Hypertension; Type 2 diabetes mellitus
Most Recent Events
- 23 Jun 2026 Adverse events and efficacy data from a phase II trial for Obesity released by Corxel Pharmaceuticals
- 23 Jun 2026 Corxel Pharmaceuticals initiates a phase I trial in Obesity in the US (PO) (NCT07652047)
- 18 May 2026 Corxel Pharmaceuticals plans to submit an NDA to China's NMPA for VCT 220 for Obesity in near future